Vanguard Capital Management
IMUX icon

Vanguard Capital Management’s Immunic IMUX Stock Holding History

Vanguard Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.78M Buy
571,561
+57,729
+11% +$712K ﹤0.01% 2900
2026
Q1 		$5.7M Buy
+513,832
New +$4.6M ﹤0.01% 3005

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Vanguard Capital Management's IMUX Position: Q2 2026 in Review

Vanguard Capital Management increased its Immunic (IMUX) stake by 11% in Q2 2026, buying an estimated $712K and bringing the position to 571,561 shares worth $8.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2900.

Vanguard Capital Management first reported a position in IMUX in Q1 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Vanguard Capital Management held 571,561 shares of Immunic worth $8.78M as of Q2 2026.
  • Vanguard Capital Management bought 57,729 Immunic shares in Q2 2026, an estimated $712K.
  • Immunic made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2900 holding.
  • Vanguard Capital Management first reported a position in Immunic in Q1 2026 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.